Neurological Manifestations Presenting in COVID 19: A Case Series from Nepal
Keywords:
COVID-19, Coronavirus, Cerebrovascular disease, Neurological disorder, Ischemic stroke, ParalysisAbstract
Background: Nepal comes in the low-income nation with the health system working in very strenuous situation. Most of the health care is borne by the individual themselves. Even though geographically sitting close to China (where COVID-19 cases started) and India (where COVID-19 cases surged to the highest level), Nepal has been facing COVID-19 infection only recently. The exponential rise in cases, have brought the health system to the chaotic level. The ate appearance of COVID-19 in Nepal has allowed us to understand more of the COVID-19 squeal. Methods: A retrospective cases series of patients diagnosed with COVID-19 using reverse transcriptase polymerase chain reaction (rt-PCR) in nasopharyngeal swabs, who either first came with neurological symptoms or other symptoms were analyzed. The neurological disorder was diagnosed clinically with positive laboratory or imaging evidence.Results: Four patients were identified, median age 43.5 (range 28-57). Neurological disorders that were noted were seizure, ischemic stroke, and Guillain
Barre syndrome (GBS).All patients had history of taking antihypertensive drugs. None of them had any family history and were otherwise healthy. The blood work up of all these patients was within normal limits, except in one patient who had marginally high glycosylated hemoglobin (HbA1C 7.2%).Conclusion: COVID-19 can present with different kinds of symptoms. We believe this case series is first being reported from Nepal. Recently neurological disorder has been reported quite often. Hence, it is imperative that regardless of etiology, COVID-19 should be considered in the differential diagnosis for patients presenting with neurological disorder during the pandemic. Early consideration of COVID-19 thus may lead to earlier detection and appropriate precautions
References
Emery SL, Erdman DD, Bowen MD, Newton BR, Winchell JM, et al. “Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus”. Emerg Infect Dis 10(2004): 311-316.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, et al. “Clinical Characteristics of Coronavirus Disease 2019 in China”. N Engl J Med 382(2020): 1708-1720.
Perez CA. “Looking ahead: The risk of neurologic complications due to COVID-19”. Neurol Clin Pract 10(2020): 371-374.
Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, et al. “Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review”. JAMA Neurology 77(2020): 1018-1027.
Mao L, Jin H, Wang M, Hu Y, Chen S, et al. “Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China”. JAMA Neurol 77(2020):683-690.
Ghannam M, Alshaer Q, Al-Chalabi M, Zakarna L, Robertson J, et al. “Neurological involvement of coronavirus disease 2019: A systematic review”. J Neurol 267(2020):3135-3153.
Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, et al. “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor”. Cell 181(2020):271-280.
Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL, et al.“Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system”. Am J Physiol Regul Integr Comp Physiol 292(2007):373-381.
Lu L, Xiong W, Liu D, Liu J, Yang D, et al. “New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study. Epilepsia 61(2020): 49-53.
Rana A, Musto AE.“The role of inflammation in the development of epilepsy. J Neuroinflammation 15(2018):144.
Anand P, Al-Faraj A, Sader E, Dashkoff J, Abdennadher M, et al. “Seizure as the presenting symptom of COVID-19: A retrospective case series. Epilepsy Behav 112(2020):107335.
Asadi-Pooya AA. “Seizures associated with coronavirus infections. Seizure 79(2020) :49-52.
Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barre syndrome associated with SARS-CoV-2 infection: causality or coincidence?. Lancet Neurol 19(2020):383-384.
Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, et al. “Guillain-Barre Syndrome Associated with SARS-CoV-2. N Engl J Med 382(2020):2574-2576.
El Otmani H, El Moutawakil B, Rafai MA, El Benna N, El Kettani C, et al.“Covid-19 and Guillain-Barre syndrome: More than a coincidence”. Rev Neurol (Paris) 176(2020):518-519.
Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, et al.“COVID-19-associated Guillain-Barre syndrome: The early pandemic experience”. Muscle Nerve 62(2020):485-491.
Virani A, Rabold E, Hanson T, Haag A, Elrufay R, et al.“Guillain- Barre Syndrome associated with SARS-CoV-2 infection”. IDCases 20(2020): 00771.
Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, et al. “Large- Vessel Stroke as a Presenting Feature of Covid-19 in the Young”. N Engl J Med 382(2020):60.
Reddy ST, Garg T, Shah C, Nascimento FA, Imran R, et al. “Cerebrovascular Disease in Patients with COVID-19: A Review of the Literature and Case Series”. Case Rep Neurol 12(2020):199-209.
Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, et al. “Incidence of thrombotic complications in critically ill ICU patients with COVID-19”. Thromb Res 191(2020):145-147.
Beyrouti R, Adams ME, Benjamin L, Cohen H, Farmer SF, et al. “Characteristics of ischaemic stroke associated with COVID-19”. J Neurol Neurosurg Psychiatry 91(2020):889-891.
Saavedra JM.“Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities”. Cell Mol Neurobiol 25(2005):485-512.
Al Saiegh F, Ghosh R, Leibold A, Avery MB, Schmidt RF, et al. “Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke”. J Neurol Neurosurg Psychiatry (2020):846-848.
Sharifi-Razavi A, Karimi N, Rouhani N. “COVID-19 and intracerebral haemorrhage: causative or coincidental?”. New Microbes New Infect 35(2020):100669.
Han H, Yang L, Liu R, Liu F, Wu KL, et al. “Prominent changes in blood coagulation of patients with SARS-CoV-2 infection”. Clin Chem Lab Med 58(2020) :1116-1120.
